MedTrace Logo

ESOXC-ER Efficacy and Safety of an Extended Release (ER) Formulation of Oxcarbazepine (Apydan Extent) in Epileptic Patients

NCT01086501 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 225

Last updated 2013-03-01

No results posted yet for this study

Summary

The aim of the observational study is to investigate the safety of oxcarbazepine extended release (ER) during long-term therapy in epileptic patients. In addition, quality of life parameters should be documented if assessed.

Conditions

Sponsors & Collaborators

  • Desitin Arzneimittel GmbH

    lead INDUSTRY

Principal Investigators

  • Stephan Arnold, MD · Private Practice

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2011-07-31
Completion
2012-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01086501 on ClinicalTrials.gov